Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TriSalus Life Sciences (TLSI) Shares Outstanding (Diluted Average) (2022 - 2025)

TriSalus Life Sciences (TLSI) has 4 years of Shares Outstanding (Diluted Average) data on record, last reported at $37.9 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 49.61% year-over-year to $37.9 million; the TTM value through Dec 2025 reached $37.9 million, up 49.61%, while the annual FY2025 figure was $37.9 million, 49.61% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $37.9 million in Q4 2025 per TLSI's latest filing, up from $34.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $37.9 million in Q4 2025 and bottomed at $299936.0 in Q3 2022.
  • Average Shares Outstanding (Diluted Average) over 4 years is $20.2 million, with a median of $24.5 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Diluted Average): plummeted 98.31% in 2023, then soared 5566.24% in 2024.
  • A 4-year view of Shares Outstanding (Diluted Average) shows it stood at $309609.0 in 2022, then skyrocketed by 2934.71% to $9.4 million in 2023, then surged by 169.61% to $25.3 million in 2024, then surged by 49.61% to $37.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $37.9 million in Q4 2025, $34.9 million in Q3 2025, and $32.9 million in Q2 2025.